Edwards Lifesciences (EW) reported Q4 adjusted earnings late Tuesday of $0.59 per diluted share, up from $0.55 a year earlier.
Analysts polled by FactSet expected $0.55.
Net sales for the quarter ended Dec. 31 rose to $1.39 billion from $1.27 billion a year earlier.
Analysts surveyed by FactSet expected $1.36 billion.
The company said it expects Q1 adjusted EPS of $0.58 to $0.64 on revenue of $1.35 billion to $1.43 billion. Analysts project EPS of $0.59 on revenue of $1.41 billion.
Edwards said its full-year guidance remains unchanged.
Shares of the company were up about 7% in after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.